Aclaris stock falls after atopic dermatitis trial fails
Aclaris Therapeutics’ mAb fails in Phase II eczema trial
Why is Aclaris Therapeutics Stock Trading Lower on Monday?
Aclaris Therapeutics Initiates Phase 2b Trial of Modzatinib (ATI-2138) in Lichen Planus (LP)
Aclaris Therapeutics Announces Top Line Phase 2 Results for its Anti-TSLP Monoclonal Antibody Bosakitug (ATI-045) in Atopic Dermatitis (AD)
Aclaris Begins Phase 2b Modzatinib Trial In Lichen Planus, Fast Track-Designated Dual ITK/JAK3 Inhibitor With Potential As First Mechanistically Complete Oral Therapy
Aclaris Phase 2 ADMIRATION Trial Of Anti-TSLP Antibody Bosakitug In Atopic Dermatitis Misses Primary Endpoint Of EASI Percent Change At Week 24, Secondary Endpoints Also Not Met
Aclaris Therapeutics to Participate in the Jefferies Global Healthcare Conference
Aclaris: Q3 Earnings Snapshot
Aclaris Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate and Clinical Update
Aclaris Therapeutics Q3 EPS $(0.12) Beats $(0.16) Estimate, Sales $1.481M Beat $1.298M Estimate
Canaccord Genuity Maintains Buy on Aclaris Therapeutics, Raises Price Target to $13
Aclaris Therapeutics, Inc. (ACRS) Discusses ATI-052 Proof-of-Concept Results in Atopic Dermatitis and Asthma - Slideshow
Wedbush Maintains Outperform on Aclaris Therapeutics, Lowers Price Target to $8
HC Wainwright & Co. Reiterates Buy on Aclaris Therapeutics, Maintains $16 Price Target
Aclaris Therapeutics ATI-052 Posts Early Eczema, Asthma Signals in Phase 1b
Aclaris Therapeutics Reports Positive Phase 1b ATI-052 Trial Results, Prices $50 Million Offering
Aclaris Says Early Data Validates Dual-Target Approach for Eczema, Asthma Drug
Aclaris Reports Positive Asthma, Eczema Drug Trial Results — So, Why Is ACRS Stock Down Nearly 8%?
Aclaris Therapeutics, Inc. (ACRS) Discusses ATI-052 Proof-of-Concept Results in Atopic Dermatitis and Asthma Transcript
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.